- MarketWatch•4 days ago
U.K. stocks gained for a 14th straight day on Friday, extending their record winning run as a soft pound helped spur investors to buy into British multinationals.
- Benzinga•5 days agoKemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
On Monday, KemPharm Inc (NASDAQ: KMPH ) reported encouraging results from its exploratory Phase 1 study assessing the pharmacokinetics, safety and intranasal abuse potential of KP511 Active Pharmaceutical ...
- American City Business Journals•5 days ago
A new class action lawsuit accuses Shire plc’s U.S. subsidiary in Lexington of monopolizing the market for its ADHD drug Intuniv by conspiring with Actavis to delay the commercial release of a cheaper generic version. New Jersey-based Actavis (NYSE:ACT) won FDA approval to launch a cheaper, generic version of Intuniv in October 2012. Shire was effectively paying Actavis “tens of millions of dollars” to maintain a monopoly, the suit claimed.
SHPG : Summary for Shire plc - American Depositary - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||167.52 x 100|
|Ask||167.64 x 100|
|Day's Range||167.25 - 169.55|
|52 Week Range||161.55 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||255.95|
|Dividend & Yield||0.80 (0.47%)|
|1y Target Est||N/A|